ImmunoGen, Inc. (IMGN) VP Sells $101,470.00 in Stock
ImmunoGen, Inc. (NASDAQ:IMGN) VP Craig Barrows sold 14,600 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $6.95, for a total transaction of $101,470.00. Following the transaction, the vice president now directly owns 51,100 shares of the company’s stock, valued at approximately $355,145. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Craig Barrows also recently made the following trade(s):
- On Friday, September 15th, Craig Barrows sold 37,050 shares of ImmunoGen stock. The stock was sold at an average price of $6.81, for a total transaction of $252,310.50.
ImmunoGen, Inc. (IMGN) traded down 1.45% during mid-day trading on Friday, reaching $6.80. 5,943,687 shares of the company were exchanged. ImmunoGen, Inc. has a 12-month low of $1.51 and a 12-month high of $8.84. The company’s 50 day moving average price is $6.56 and its 200-day moving average price is $5.16. The stock’s market capitalization is $609.26 million.
ImmunoGen (NASDAQ:IMGN) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $39.02 million for the quarter, compared to analyst estimates of $30.59 million. The business’s quarterly revenue was up 426.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.53) EPS. On average, equities research analysts forecast that ImmunoGen, Inc. will post ($0.74) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “ImmunoGen, Inc. (IMGN) VP Sells $101,470.00 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/15/immunogen-inc-imgn-vp-sells-101470-00-in-stock.html.
Institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership acquired a new stake in ImmunoGen in the 2nd quarter worth about $102,000. Envestnet Asset Management Inc. raised its stake in ImmunoGen by 2.8% in the 1st quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 743 shares in the last quarter. Gould Asset Management LLC CA acquired a new stake in ImmunoGen in the 2nd quarter worth about $107,000. Intl Fcstone Inc. acquired a new stake in ImmunoGen in the 2nd quarter worth about $115,000. Finally, Acadian Asset Management LLC acquired a new stake in ImmunoGen in the 1st quarter worth about $117,000. Institutional investors and hedge funds own 84.66% of the company’s stock.
Several research firms have recently issued reports on IMGN. Canaccord Genuity restated a “buy” rating and set a $10.00 price objective (up previously from $8.00) on shares of ImmunoGen in a report on Wednesday, August 30th. Cowen and Company restated a “hold” rating on shares of ImmunoGen in a report on Tuesday, August 29th. Leerink Swann restated a “buy” rating on shares of ImmunoGen in a report on Tuesday, August 29th. Cantor Fitzgerald restated a “hold” rating on shares of ImmunoGen in a report on Tuesday, August 29th. Finally, BidaskClub upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 26th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. ImmunoGen presently has an average rating of “Hold” and an average price target of $8.01.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.